A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer

American Society of Clinical Oncology (ASCO) - Tập 22 Số 1 - Trang 23-30 - 2004
Richard M. Goldberg1, Daniel J. Sargent1, Roscoe F. Morton1, Charles S. Fuchs1, Ramesh K. Ramanathan1, Stephen K. Williamson1, B. Findlay1, Henry C. Pitot1, Steven R. Alberts1
1From the North Central Cancer Treatment Group, Divisions of Hematology/Oncology and Medical Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC; North Central Cancer Treatment Group, Division of Biostatistics, Mayo Clinic, Rochester, MN; North Central Cancer Treatment Group, Iowa Oncology Research Association Community Clinical Oncology Program, Des Moines, IA; Cancer and Acute Leukemia Group B, Department of Oncology, Dana-Farber Cancer Institute, Boston, MA; Eastern Cooperative...

Tóm tắt

Purpose Three agents with differing mechanisms of action are available for treatment of advanced colorectal cancer: fluorouracil, irinotecan, and oxaliplatin. In this study, we compared the activity and toxicity of three different two-drug combinations in patients with metastatic colorectal cancer who had not been treated previously for advanced disease. Patients and Methods Patients were concurrently randomly assigned to receive irinotecan and bolus fluorouracil plus leucovorin (IFL, control combination), oxaliplatin and infused fluorouracil plus leucovorin (FOLFOX), or irinotecan and oxaliplatin (IROX). The primary end point was time to progression, with secondary end points of response rate, survival time, and toxicity. Results A total of 795 patients were randomly assigned between May 1999 and April 2001. A median time to progression of 8.7 months, response rate of 45%, and median survival time of 19.5 months were observed for FOLFOX. These results were significantly superior to those observed for IFL for all end points (6.9 months, 31%, and 15.0 months, respectively) or for IROX (6.5 months, 35%, and 17.4 months, respectively) for time to progression and response. The FOLFOX regimen had significantly lower rates of severe nausea, vomiting, diarrhea, febrile neutropenia, and dehydration. Sensory neuropathy and neutropenia were more common with the regimens containing oxaliplatin. Conclusion The FOLFOX regimen of oxaliplatin and infused fluorouracil plus leucovorin was active and comparatively safe. It should be considered as a standard therapy for patients with advanced colorectal cancer.

Từ khóa


Tài liệu tham khảo

10.3322/canjclin.52.1.23

10.1200/JCO.1997.15.1.368

10.1200/JCO.1992.10.6.896

10.1200/JCO.1997.15.2.808

Hsiang YH, Hertzberg R, Hecht S, et al: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873,1985–14878,

10.1056/NEJM200009283431302

10.1016/S0140-6736(00)02034-1

10.1124/mol.54.5.770

10.1016/S0006-2952(97)81490-6

10.1200/JCO.2000.18.16.2938

10.1200/JCO.1999.17.6.1751

10.1200/JCO.1999.17.3.902

Morton RF, Goldberg RM, Sargent DJ, et al: Oxaliplatin (OXAL) or CPT-11 combined with 5FU/leucovorin (LV) in advanced colorectal cancer (CRC): An NCCTG/CALGB study. Proc Am Soc Clin Oncol 20:125,2001, (abstr)

10.1056/NEJM200107123450213

10.2307/2530245

10.1080/01621459.1958.10501452

Cox DR: Regression models and life-tables. J R Stat Soc 34B:187,1972–220,

10.1200/JCO.2000.18.1.136

10.1200/JCO.1998.16.1.301

Tournigand C, Louvet C, Quinax E, et al: FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a phase III study. Proc Am Soc Clin Oncol 20:124,2001, (abstr)

10.1016/S0140-6736(98)02309-5

10.1016/S0140-6736(98)03085-2

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 22 Số 1

23-30

Thông tin tác giả